)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Revenio Group
Revenio Group (REG1V) investor relations material
Revenio Group Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary11 Feb, 2026
Executive summary
Net sales for 2025 reached EUR 109.7 million, up 6.0% year-over-year and 9.1% currency-adjusted, with Q4 net sales at EUR 31.2 million, up 2.2% reported and 8.6% currency-adjusted.
US sales achieved an all-time record in December; EMEA showed strong growth, while APAC improved sequentially but declined year-over-year.
All product categories and regions contributed to growth, with notable expansion in hardware, screening solutions, and software, and a doubling of report volumes.
New product launches included the iCare MAIA microperimeter and iCare ALTIUS/Data Management Solution, with leadership development and operational readiness for tariffs.
Continuous business, including software and service contracts, accounted for nearly one-third of net sales.
Financial highlights
Q4 2025 EBIT was EUR 6.7 million (down 26.9%); full-year EBIT was EUR 25.4 million (up 1.4%), with adjusted EBIT at EUR 26.5 million (up 2.3%).
Q4 cash flow was EUR 15.9 million; full-year cash flow reached EUR 30.2 million, both showing significant improvement.
Gross margin for 2025 was 70.9% (up 0.7 percentage points), but Q4 margin was 67.6% (down 4.8 points), pressured by tariffs and delayed price increases.
Earnings per share for 2025 were EUR 0.655, down from EUR 0.695 in 2024.
Net gearing improved to -13.3%, and equity ratio was 76.1% at year-end.
Outlook and guidance
2026 guidance: exchange rate-adjusted net sales expected to grow 8–15% year-over-year; profitability, excluding non-recurring items, to remain at a good level.
Price increases in the US are being implemented to offset tariffs, with expectations for gross margin to approach 70% as these take effect.
Larger deals in the pipeline could drive results toward the upper end of guidance.
Clinical trial costs for FDA approval of the screening platform expected to be EUR 1–1.5 million in 2026, with approval targeted for H1 2027.
Profitability in 2026 is expected to be supported by ongoing price adjustments and a strong product pipeline.
Q4 profit drop: tariffs, price hikes, non-recurring?
iCare Screening Solution US market entry costs?
Leadership changes impact on strategy update.
Q4 gross margin miss: What caused the delay?
Dividend flexibility: How does it support M&A?
DRSplus FDA approval: What is the timeline?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Revenio Group earnings date
Q1 202628 Apr, 2026
Revenio Group
Next Revenio Group earnings date
Q1 202628 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Revenio Group Oyj designs, manufactures, and sells medical instruments for the early detection of glaucoma, diabetic retinopathy, and macular degeneration. The company's vision is to create a world without blindness. It offers ophthalmology and optometry products like the Topcon Refractometer, the Diagnolyzer FT, the Diabetoscan DR/A1C+, and the XDM-400 Cell Health Analyzer; cell health analysis systems for measuring cellular health of skin cells, bone marrow cells and dental pulp cells; as well as other medical devices that measure the mechanical stress of tissues by stethoscopy (examination of tissues via a stethoscope) and laser Doppler flowmetry (measures blood flow in tissue), and enables quantitative analysis of renal function. The company is based in Vantaa, Finland.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage